Neurona Therapeutics Closes $24 Million in Series A Financing
Neurona is a cell therapy company founded by world class neural stem cell experts and focused on the discovery and development of disease-altering treatments for intractable neuropsychiatric disorders. The $24 million Series A financing was led by The Column Group II, LP, and Topspin Fund, LP as co-investor.
The Company’s initial efforts are aimed at identifying a transplantable interneuron (inhibitory nerve) candidate derived from human embryonic stem cells or human fetal tissue for the treatment of temporal lobe epilepsy. Neurona’s goal is to advance its first development candidate to IND approval in 3 years.
Leveraging the unique insights of its founders and an internal team of outstanding scientists, the Company seeks to become an industry leader in the neural stem cell field with multiple therapeutic product candidates ranging from epilepsy and neuropathic pain to other potential opportunities in the broader neurodegenerative and neuropsychiatric disease space.